We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GEHC Expands Vscan Air AI Capabilities With Lung Guidance & AutoAS
Read MoreHide Full Article
Key Takeaways
GEHC adds Lung Guidance and AutoAS to Vscan Air, expanding AI-assisted cardiac and pulmonary assessments.
Lung Guidance achieved a 95.2% success rate for diagnostic-quality exams among non-expert users in testing.
AutoAS aids aortic stenosis assessment, while Innovation Packages could support revenue opportunities.
GE HealthCare Technologies Inc. (GEHC - Free Report) recently announced the addition of two AI-assisted capabilities, Lung Guidance and AutoAS, to its Vscan Air handheld ultrasound system. The new tools are designed to support lung ultrasound image acquisition and the assessment of moderate-to-severe aortic stenosis (AS) at the point of care. The additions expand GE HealthCare's cardiopulmonary AI suite, helping clinicians evaluate patients with cardiac and respiratory symptoms and make more informed decisions when access to formal imaging or specialist interpretation is limited.
Per management, clinicians often have limited time and incomplete information when assessing patients with symptoms like shortness of breath, which may arise from cardiac conditions, respiratory issues or both. Lung Guidance and AutoAS are designed to bridge the gap between the initial physical assessment and the next clinical step by providing AI-enabled tools to clinicians at the point of care.
GEHC Stock Trend Following the News
GEHC stock has gained 4.2% since the announcement on Nov. 3. Year to date, the stock has returned 2.4% against the industry’s 13.4% fall. Meanwhile, the S&P 500 has risen 9.1% during the same timeframe.
The expanded AI capabilities could strengthen GE HealthCare's position in the point-of-care ultrasound market by making advanced diagnostic support more accessible. Simplified image acquisition and early identification of cardiac and pulmonary conditions may encourage wider adoption of handheld ultrasound systems. The additions could also enhance the value of its Vscan Air portfolio, support customer retention and create recurring revenue opportunities through Innovation Packages, further differentiating its ultrasound offerings.
GEHC currently has a market capitalization of $37.25 billion.
Image Source: Zacks Investment Research
More on the News
Lung Guidance provides real-time scanning assistance by directing clinicians to anatomical landmarks across the standard eight-zone lung ultrasound protocol. It detects the pleural line, A-lines, rib shadows, diaphragm and abdomen to help acquire diagnostic-quality images. AutoCapture records clips when predefined image-quality criteria are met, while Save Best Clip allows users to retain the best-quality image when those conditions are not achieved. The tool also supports B-line detection, scoring and reporting. In validation testing, non-expert users achieved a 95.2% success rate in acquiring diagnostic-quality exams, compared with 96.8% for expert users.
AutoAS provides an AI-assisted estimate of the presence or absence of moderate-to-severe aortic stenosis (AS) using standard 2D cardiac images from Vscan Air SL. It analyzes at least two compatible echocardiographic views and provides an assessment with a confidence score. Trained and validated against expert cardiologists' assessments, the tool is designed to reduce variability in missed AS compared with visual interpretation alone.
The additions build on Vscan Air's existing AI capabilities, including Caption AI, Caption Interpretation Auto EF and Auto Bladder Volume. GE HealthCare also offers AI solutions across its Venue and LOGIQ e ultrasound families. Lung Guidance and AutoAS have received FDA 510(k) clearance and CE marking. Both are available through Vscan Air Innovation Packages in the United States and select countries.
Industry Prospects Favoring the Market
According to Grand View Research, the global ultrasound AI market is estimated to reach $2.3 billion in 2026 and is projected to witness a CAGR of 28.6% through 2033.
Factors such as rising demand for early and accurate disease detection, increasing adoption of AI-assisted diagnostic imaging, growing patient imaging volumes and technological advancements in ultrasound systems are driving market growth.
Other News
GE HealthCare recently introduced Allia Celeo, a ceiling-mounted image-guided system designed to support procedural efficiency and precision imaging across cardiology and interventional radiology. Featuring an extra-wide C-arm, AI-powered precision imaging and a real-time digital twin, the system aims to optimize image quality and radiation dose while supporting diverse procedures. It also integrates predictive service technology to minimize operational disruptions.
Some other top-ranked stocks from the broader medical space are Glaukos (GKOS - Free Report) , Intuitive Surgical (ISRG - Free Report) and West Pharmaceutical Services (WST - Free Report) .
Glaukos, currently flaunting a Zacks Rank #1 (Strong Buy), reported third-quarter 2026 adjusted earnings per share (EPS) of 47 cents, which surpassed the Zacks Consensus Estimate by 491.7%. Revenues of $211 million beat the Zacks Consensus Estimate by 25%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GKOS has an estimated earnings growth rate of 155.6% for 2026. The company’s earnings beat estimates in three of the trailing four quarters and missed once, the average surprise being 138.6%.
Intuitive Surgical, currently carrying a Zacks Rank #2, reported third-quarter 2026 adjusted EPS of $3.00, which beat the Zacks Consensus Estimate by 13.6%. Revenues of $3.05 billion surpassed the Zacks Consensus Estimate by 4.9%.
Intuitive Surgical has a long-term estimated growth rate of 15.5%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.1%.
West Pharmaceutical, currently carrying a Zacks Rank #2, reported a third-quarter 2026 adjusted EPS of $2.66, which surpassed the Zacks Consensus Estimate by 22%. Revenues of $874.5 million beat the Zacks Consensus Estimate by 5.9%.
WST has an estimated long-term earnings growth rate of 17.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 18.6%.
View the Zacks #1 Rank List
Image: Bigstock
GEHC Expands Vscan Air AI Capabilities With Lung Guidance & AutoAS
Key Takeaways
GE HealthCare Technologies Inc. (GEHC - Free Report) recently announced the addition of two AI-assisted capabilities, Lung Guidance and AutoAS, to its Vscan Air handheld ultrasound system. The new tools are designed to support lung ultrasound image acquisition and the assessment of moderate-to-severe aortic stenosis (AS) at the point of care. The additions expand GE HealthCare's cardiopulmonary AI suite, helping clinicians evaluate patients with cardiac and respiratory symptoms and make more informed decisions when access to formal imaging or specialist interpretation is limited.
Per management, clinicians often have limited time and incomplete information when assessing patients with symptoms like shortness of breath, which may arise from cardiac conditions, respiratory issues or both. Lung Guidance and AutoAS are designed to bridge the gap between the initial physical assessment and the next clinical step by providing AI-enabled tools to clinicians at the point of care.
GEHC Stock Trend Following the News
GEHC stock has gained 4.2% since the announcement on Nov. 3. Year to date, the stock has returned 2.4% against the industry’s 13.4% fall. Meanwhile, the S&P 500 has risen 9.1% during the same timeframe.
The expanded AI capabilities could strengthen GE HealthCare's position in the point-of-care ultrasound market by making advanced diagnostic support more accessible. Simplified image acquisition and early identification of cardiac and pulmonary conditions may encourage wider adoption of handheld ultrasound systems. The additions could also enhance the value of its Vscan Air portfolio, support customer retention and create recurring revenue opportunities through Innovation Packages, further differentiating its ultrasound offerings.
GEHC currently has a market capitalization of $37.25 billion.
Image Source: Zacks Investment Research
More on the News
Lung Guidance provides real-time scanning assistance by directing clinicians to anatomical landmarks across the standard eight-zone lung ultrasound protocol. It detects the pleural line, A-lines, rib shadows, diaphragm and abdomen to help acquire diagnostic-quality images. AutoCapture records clips when predefined image-quality criteria are met, while Save Best Clip allows users to retain the best-quality image when those conditions are not achieved. The tool also supports B-line detection, scoring and reporting. In validation testing, non-expert users achieved a 95.2% success rate in acquiring diagnostic-quality exams, compared with 96.8% for expert users.
AutoAS provides an AI-assisted estimate of the presence or absence of moderate-to-severe aortic stenosis (AS) using standard 2D cardiac images from Vscan Air SL. It analyzes at least two compatible echocardiographic views and provides an assessment with a confidence score. Trained and validated against expert cardiologists' assessments, the tool is designed to reduce variability in missed AS compared with visual interpretation alone.
The additions build on Vscan Air's existing AI capabilities, including Caption AI, Caption Interpretation Auto EF and Auto Bladder Volume. GE HealthCare also offers AI solutions across its Venue and LOGIQ e ultrasound families. Lung Guidance and AutoAS have received FDA 510(k) clearance and CE marking. Both are available through Vscan Air Innovation Packages in the United States and select countries.
Industry Prospects Favoring the Market
According to Grand View Research, the global ultrasound AI market is estimated to reach $2.3 billion in 2026 and is projected to witness a CAGR of 28.6% through 2033.
Factors such as rising demand for early and accurate disease detection, increasing adoption of AI-assisted diagnostic imaging, growing patient imaging volumes and technological advancements in ultrasound systems are driving market growth.
Other News
GE HealthCare recently introduced Allia Celeo, a ceiling-mounted image-guided system designed to support procedural efficiency and precision imaging across cardiology and interventional radiology. Featuring an extra-wide C-arm, AI-powered precision imaging and a real-time digital twin, the system aims to optimize image quality and radiation dose while supporting diverse procedures. It also integrates predictive service technology to minimize operational disruptions.
GE HealthCare Technologies Inc. Price
GE HealthCare Technologies Inc. price | GE HealthCare Technologies Inc. Quote
GEHC’s Zacks Rank & Other Key Picks
Currently, GEHC carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the broader medical space are Glaukos (GKOS - Free Report) , Intuitive Surgical (ISRG - Free Report) and West Pharmaceutical Services (WST - Free Report) .
Glaukos, currently flaunting a Zacks Rank #1 (Strong Buy), reported third-quarter 2026 adjusted earnings per share (EPS) of 47 cents, which surpassed the Zacks Consensus Estimate by 491.7%. Revenues of $211 million beat the Zacks Consensus Estimate by 25%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GKOS has an estimated earnings growth rate of 155.6% for 2026. The company’s earnings beat estimates in three of the trailing four quarters and missed once, the average surprise being 138.6%.
Intuitive Surgical, currently carrying a Zacks Rank #2, reported third-quarter 2026 adjusted EPS of $3.00, which beat the Zacks Consensus Estimate by 13.6%. Revenues of $3.05 billion surpassed the Zacks Consensus Estimate by 4.9%.
Intuitive Surgical has a long-term estimated growth rate of 15.5%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.1%.
West Pharmaceutical, currently carrying a Zacks Rank #2, reported a third-quarter 2026 adjusted EPS of $2.66, which surpassed the Zacks Consensus Estimate by 22%. Revenues of $874.5 million beat the Zacks Consensus Estimate by 5.9%.
WST has an estimated long-term earnings growth rate of 17.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 18.6%.